By Michael Vlessides
Boston—Combination therapy with direct-acting antivirals (DAAs) and the cholesterol drug ezetimibe is effective at preventing or rapidly curing infection with hepatitis C virus in transplant recipients who have received organs from infected donors, a new study has concluded.
The short-course strategy employed by the investigators allowed patients to complete HCV therapy prior to discharge from the hospital after transplantation.
Jordan J. Feld, MD, MPH, the R. Phelan